The Red Flags Were Missing, the Indication Was Not: Genetic Testing in Heart Failure and Cardiomyopathy
By: Abou Bakr Salama
References
- Kittleson MM, Ambardekar AV, Cheng RK, et al. Transthyretin cardiac amyloidosis evaluation and management: 2025 ACC concise clinical guidance. J Am Coll Cardiol. 2026 Feb 10;87(5):549-565. doi: 10.1016/j.jacc.2025.09.004
- Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73(22):2872-2891. doi: 10.1016/j.jacc.2019.04.003
- Arbelo E, Protonotarios A, Gimeno JR, et al. 2023 ESC guidelines for the management of cardiomyopathies. Eur Heart J. 2023;44(37):3503-3626. doi: 10.1093/eurheartj/ehad194
- Wilde AAM, Semsarian C, Márquez MF, et al. EHRA/HRS/APHRS/LAHRS expert consensus statement on the state of genetic testing for cardiac diseases. Europace. 2022;24(8):1307-1367. doi: 10.1093/europace/euac030
- Hershberger RE, Givertz MM, Ho CY, et al. Genetic evaluation of cardiomyopathy: a Heart Failure Society of America practice guideline. J Card Fail. 2018;24(5):281-302. doi: 10.1016/j.cardfail.2018.03.004
- Quarta CC, Buxbaum JN, Shah AM, et al. The amyloidogenic V122I transthyretin variant in elderly black Americans. N Engl J Med. 2015;372(1):21-29. doi: 10.1056/NEJMoa1404852
- Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404-2412. doi: 10.1161/CIRCULATIONAHA.116.021612
- Hutchison CA, Plant T, Drayson M, et al. Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure. BMC Nephrol. 2008;9:11. doi: 10.1186/1471-2369-9-11
- Ommen SR, Ho CY, Asif IM, et al. 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR guideline for the management of hypertrophic cardiomyopathy. Circulation. 2024;149(23):e1239-e1311. doi: 10.1161/CIR.0000000000001250
- Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007-1016. doi: 10.1056/NEJMoa1805689
- Fontana M, Berk JL, Gillmore JD, et al. Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. N Engl J Med. 2025;392(1):33-44. doi: 10.1056/NEJMoa2409134
DOI: https://doi.org/10.14797/mdcvj.1955 | Journal eISSN: 1947-6108
Language: English
Page range: 102 - 105
Submitted on: Aug 25, 2026
Accepted on: Aug 28, 2026
Published on: Sep 15, 2026
Published by: Houston Methodist DeBakey Heart & Vascular Center
In partnership with: Paradigm Publishing Services
Keywords:
© 2026 Abou Bakr Salama, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.